Key result
Pre-existing pulmonary hypertension in patients undergoing TMVR with Mitraclip did not significantly increase inpatient mortality compared to patients without PH (3.2% vs. 2.1%; OR 1.57; P=0.335).
Why the study?
Periprocedural outcomes of transcatheter mitral valve repair with Mitraclip in patients with pulmonary hypertension are not well studied.
Does pre-existing pulmonary hypertension worsen in-hospital outcomes in patients undergoing transcatheter mitral valve repair with Mitraclip?
Observational (n=1,037)
Yes
Does pre-existing pulmonary hypertension worsen in-hospital outcomes in patients undergoing transcatheter mitral valve repair with Mitraclip?
Effect estimate: OR 1.57
Absolute Event Rate: 3.2% vs 2.1%
p-value: p=0.335
Pre-existing pulmonary hypertension does not adversely affect in-hospital outcomes in patients undergoing transcatheter mitral valve repair with Mitraclip.
BACKGROUND: Periprocedural outcomes of transcatheter mitral valve repair (TMVR) with Mitraclip in patients with pulmonary hypertension (PH) are not well studied. METHODS: Patients who underwent TMVR with Mitraclip between 2011 and 2015 were identified using the National Inpatient Sample (NIS). All missing variables were excluded from the analysis and therefore, complete case analysis was performed. RESULTS: A total of 1,037 patients underwent TMVR with Mitraclip between 2011 and 2015. The prevalence of PH in these patients was 32.6%. In-hospital outcomes were compared between PH group and non-PH group. Inpatient mortality after TMVR was similar between the two groups (3.2% vs. 2.1%, OR 1.57, P = 0.335). There was no statistical significance between the two groups in the rates of hemorrhage requiring transfusion (8.5% vs. 7.2%, OR 1.17, P = 0.587), cardiogenic shock (4.4% vs. 4.5%, OR 0.98, P = 0.951), acute respiratory failure (15.2% vs. 13.1%, OR 1.23, P = 0.460), postoperative sepsis (2.75% vs. 3.9%, OR 0.66, P = 0.340), postoperative deep vein thrombosis or pulmonary embolism (2.7% vs. 3.9%, OR 1.98, P = 0.348). In addition, non-routine home discharge, median hospital cost and length of stay were similar between the two groups. CONCLUSION: Pre-existing PH in patients undergoing TMVR with Mitraclip does not adversely affect in-hospital outcomes in this cohort of patients. Therefore, PH does not carry a prohibitive risk in selecting patients for Mitraclip procedure.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2018) conducted an observational in Transcatheter mitral valve repair with Mitraclip (n=1,037). Pre-existing pulmonary hypertension vs. No pulmonary hypertension was evaluated on Inpatient mortality (OR 1.57, p=0.335). Pre-existing pulmonary hypertension in patients undergoing TMVR with Mitraclip did not significantly increase inpatient mortality compared to patients without PH (3.2% vs. 2.1%; OR 1.57; P=0.335).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: